Document ID: chunk:federal_register_of_legislation:F2006L02853:body:0:p4
Version: federal_register_of_legislation:F2006L02853
Segment Type: other
Provision Reference: 
Character Range: 9292–12474

directions,
          (a)       may is permissive and not mandatory.
          (b)       a reference to financial year means the 12 month period beginning on 1 July in one calendar year and ending on 30 June in the following calendar year.

PART 2 – CONSIDERATION OF APPLICATIONS TO PARTICIPATE IN THE PROGRAM
Procedure
       5. (1) Subject to clause 6, the Board will assess eligible applications and provide a merit ranking of those applications to the delegate of the Minister.

(2) The Board must consider eligible applications made in relation to a particular funding round as soon as practicable after those applications have been provided to the Board by the delegate of the Minister.

Board may decline to provide merit ranking

   6. The Board may decide to refuse to provide a merit ranking in respect of a particular eligible application if it is not satisfied:

       (a) with the level of merit of an eligible application in relation to one or more of the merit criteria; or

       (b) that the applicant is part of the pharmaceuticals industry;

       (c) that the activities described in the eligible application are eligible Australian pharmaceutical R&D activities; or

       (d) that the applicant has a three year history of pharmaceutical R&D activities.

PART 3 – ASSESSMENT AND MERIT RANKING OF APPLICATIONS
Assessment of applications
    7. Subject to clause 6, the Board must assess each eligible application on its merit according to the extent to which the application meets the merit criteria.

Merit criteria
    8. The merit of eligible applications must be assessed against the following criteria:

    Criterion 1: The Track Record and Capabilities of the Applicant
    The Board/Committee will assess each applicant's track record of undertaking pharmaceutical R&D activities, and their capabilities to undertake the proposed eligible Australian pharmaceutical R&D activities.
    In respect of this merit criterion, applicants could address the following factors:

            (a) their record in successfully managing pharmaceutical R&D projects in the proposed fields/therapeutic areas;

            (b) their record in achieving commercial outcomes from their pharmaceutical R&D; and

            (c) their record in meeting commitments in Government programs they have participated in.

    In respect of capabilities, applicants could address the following factors:

            (d) whether they have access to financial resources to fund the proposed program of projects;

            (e) the facilities and research infrastructure available to the applicant, and the capabilities of the personnel to be involved (this can include the facilities and personnel of contract partners);

            (f) the existence of clearly focused business plans, including R&D plans, intellectual property management and creditable commercialisation strategies; and

           (g) the facilities, capabilities and expertise brought about through partnerships and collaborations.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence